Hcw Biologics Stock Probability of Future Stock Price Finishing Over 0.61
| HCWB Stock | USD 0.61 0.11 22.00% |
HCW |
HCW Biologics Target Price Odds to finish over 0.61
The tendency of HCW Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.61 | 90 days | 0.61 | about 46.38 |
Based on a normal probability distribution, the odds of HCW Biologics to move above the current price in 90 days from now is about 46.38 (This HCW Biologics probability density function shows the probability of HCW Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days HCW Biologics has a beta of -1.89. This usually indicates as returns on its benchmark rise, returns on holding HCW Biologics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, HCW Biologics is expected to outperform its benchmark. Additionally HCW Biologics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. HCW Biologics Price Density |
| Price |
Predictive Modules for HCW Biologics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as HCW Biologics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of HCW Biologics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
HCW Biologics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. HCW Biologics is not an exception. The market had few large corrections towards the HCW Biologics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold HCW Biologics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of HCW Biologics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.17 | |
β | Beta against Dow Jones | -1.89 | |
σ | Overall volatility | 0.11 | |
Ir | Information ratio | -0.06 |
HCW Biologics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of HCW Biologics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for HCW Biologics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| HCW Biologics generated a negative expected return over the last 90 days | |
| HCW Biologics has high historical volatility and very poor performance | |
| HCW Biologics has some characteristics of a very speculative penny stock | |
| HCW Biologics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.84 M. Net Loss for the year was (24.99 M) with profit before overhead, payroll, taxes, and interest of 4.1 M. | |
| HCW Biologics currently holds about 32.41 M in cash with (22.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 52.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Greene Rick S. of 35714 shares of HCW Biologics at 1.4 subject to Rule 16b-3 |
HCW Biologics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of HCW Stock often depends not only on the future outlook of the current and potential HCW Biologics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. HCW Biologics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 35.9 M | |
| Cash And Short Term Investments | 3.6 M |
HCW Biologics Technical Analysis
HCW Biologics' future price can be derived by breaking down and analyzing its technical indicators over time. HCW Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of HCW Biologics. In general, you should focus on analyzing HCW Stock price patterns and their correlations with different microeconomic environments and drivers.
HCW Biologics Predictive Forecast Models
HCW Biologics' time-series forecasting models is one of many HCW Biologics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary HCW Biologics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about HCW Biologics
Checking the ongoing alerts about HCW Biologics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for HCW Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| HCW Biologics generated a negative expected return over the last 90 days | |
| HCW Biologics has high historical volatility and very poor performance | |
| HCW Biologics has some characteristics of a very speculative penny stock | |
| HCW Biologics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.84 M. Net Loss for the year was (24.99 M) with profit before overhead, payroll, taxes, and interest of 4.1 M. | |
| HCW Biologics currently holds about 32.41 M in cash with (22.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 52.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Greene Rick S. of 35714 shares of HCW Biologics at 1.4 subject to Rule 16b-3 |
Additional Information and Resources on Investing in HCW Stock
When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:Check out HCW Biologics Backtesting, HCW Biologics Valuation, HCW Biologics Correlation, HCW Biologics Hype Analysis, HCW Biologics Volatility, HCW Biologics History as well as HCW Biologics Performance. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.107 | Quarterly Revenue Growth (0.01) | Return On Assets (0.70) | Return On Equity (3.44) |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.